--- title: "上海心玮医疗科技股份有限公司 (06609.HK)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/06609.HK.md" symbol: "06609.HK" name: "上海心玮医疗科技股份有限公司" industry: "医疗器械" --- # 上海心玮医疗科技股份有限公司 (06609.HK) | Item | Detail | |------|--------| | Industry | 医疗器械 | | Location | 港股市场 | | Website | [www.heartcare.com.cn](https://www.heartcare.com.cn) | ## Company Profile 上海心玮医疗科技股份有限公司是从事创新型神经介入医疗器械研发的中国公司。该公司产品组合包括神经介入及心脏医疗器械,其主要产品为 Captor 取栓器械 (Captor) 及左心耳封堵器。该公司产品组合从治疗及预防缺血性脑卒中 (包括急性缺血性脑卒中及颅内动脉狭窄) 到出血性脑卒中的治疗。该公司其他产品包括封堵球囊导管、ExtraFlexTM 远端通路导管及 SupSelekTM 微导管。该公司主要在国内市场开展业务。 ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-21T04:30:11.000Z **Overall: B (0.31)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 9 / 26 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 33.51% | | | Net Profit YoY | 194.88% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 1.43 | | | Dividend Ratio | 0.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 1.74B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 363.20M | | **Multi Score**: B #### Profit Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 3.88% | C | | Profit Margin | 12.67% | B | | Gross Margin | 68.24% | A | #### Growth Score: A | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 33.51% | A | | Net Profit YoY | 194.88% | A | | Total Assets YoY | 6.69% | B | | Net Assets YoY | 6.12% | B | #### Cash Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 789.29% | B | | OCF YoY | 33.51% | A | #### Operating Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.27 | D | #### Debt Score: A | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 11.00% | A | ```chart-data:radar { "title": "Longbridge Financial Score - 上海心玮医疗科技股份有限公司", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "B", "indicators": [ { "name": "ROE", "value": "3.88%", "rating": "C" }, { "name": "Profit Margin", "value": "12.67%", "rating": "B" }, { "name": "Gross Margin", "value": "68.24%", "rating": "A" } ] }, { "name": "Growth", "grade": "A", "indicators": [ { "name": "Revenue YoY", "value": "33.51%", "rating": "A" }, { "name": "Net Profit YoY", "value": "194.88%", "rating": "A" }, { "name": "Total Assets YoY", "value": "6.69%", "rating": "B" }, { "name": "Net Assets YoY", "value": "6.12%", "rating": "B" } ] }, { "name": "Cash", "grade": "B", "indicators": [ { "name": "Cash Flow Margin", "value": "789.29%", "rating": "B" }, { "name": "OCF YoY", "value": "33.51%", "rating": "A" } ] }, { "name": "Operating", "grade": "D", "indicators": [ { "name": "Turnover", "value": "0.27", "rating": "D" } ] }, { "name": "Security", "grade": "A", "indicators": [ { "name": "Gearing Ratio", "value": "11.00%", "rating": "A" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | 时代天使 (HK.6699) | B | A | C | B | B | B | | 02 | 归创通桥 (HK.2190) | B | A | D | A | B | B | | 03 | 爱康医疗 (HK.1789) | B | A | C | B | B | B | | 04 | 心泰医疗 (HK.2291) | A | B | D | A | B | B | | 05 | 现代牙科 (HK.3600) | A | B | B | B | C | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 37.45 | 11/27 | 50.32 | 44.09 | 39.63 | | PB | 1.43 | 9/27 | 1.86 | 1.51 | 0.96 | | PS (TTM) | 4.74 | 10/27 | 6.38 | 5.08 | 3.88 | | Dividend Yield | 0.00% | - | - | - | - | ## Institutional View ### Analyst Rating Distribution > As of 2025-06-04T16:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 100% | | Overweight | 0 | 0% | | Hold | 0 | 0% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 46.02 | | Highest Target | 19.97 | | Lowest Target | 19.97 | ## References - [Company Overview](https://longbridge.com/en/quote/06609.HK/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/06609.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/06609.HK/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.